

1 **Tobacco, nicotine, and cannabis use and exposure in an**  
2 **Australian Indigenous population during pregnancy: A protocol**  
3 **to measure parental and foetal exposure and outcomes.**

4  
5

6 Angela Ratsch<sup>1,2</sup>, Elizabeth A. Burmeister<sup>1,2</sup>, Aunty Veronica Bird<sup>3</sup>, Aunty Joyce  
7 Bonner<sup>3</sup>, Uncle Glen Miller<sup>3,4</sup>, Aunty Marj Speedy<sup>3</sup>, Graham Douglas<sup>5</sup>, Stevan Ober<sup>5</sup>,  
8 Ann Woolcock<sup>5</sup>, Sharly Blair (nee Murdoch)<sup>5</sup>, Min-Tz Weng<sup>6</sup>, Jared A. Miles<sup>6</sup>, Kathryn  
9 J. Steadman<sup>6</sup>

10  
11

12 <sup>1</sup>Wide Bay Hospital and Health Service, Hervey Bay, Australia

13 <sup>2</sup>Rural Clinical School, The University of Queensland, Brisbane, Australia

14 <sup>3</sup>Butchulla Aboriginal Corporation, Fraser Coast, Australia

15 <sup>4</sup>Butchulla Mens Business Association, Fraser Coast, Australia

16 <sup>5</sup>Galangoor Duwalami Primary Healthcare Service, Fraser Coast, Australia

17 <sup>6</sup>School of Pharmacy, The University of Queensland, Brisbane, Australia

18

19 \*Corresponding author

20 E-mail: [angela.ratsch@health.qld.gov.au](mailto:angela.ratsch@health.qld.gov.au)

21  
22

23 **Tobacco, nicotine, and cannabis use and exposure in an**  
24 **Australian Indigenous population during pregnancy: A protocol**  
25 **to measure parental and foetal exposure and outcomes.**

26 **Abstract**

27 **Background:** The Australian National Perinatal Data Collection collates all live and  
28 stillbirths from States and Territories in Australia. In that database, maternal  
29 cigarette smoking is noted twice (smoking <20 weeks gestation; smoking >20 weeks  
30 gestation). Cannabis use and other forms of nicotine use, for example vaping and  
31 nicotine replacement therapy, are not reported. The 2021 report shows the rate of  
32 smoking for Australian Indigenous mothers was 42% compared with 11% for  
33 Australian non-Indigenous mothers. Evidence shows that Indigenous babies exposed  
34 to maternal smoking have a higher rate of adverse outcomes compared to non-  
35 Indigenous babies exposed to maternal smoking.

36

37 **Objectives:** The reasons for the differences in health outcome between Indigenous  
38 and non-Indigenous pregnancies exposed to tobacco and nicotine is unknown but will  
39 be explored in this project through a number of activities. Firstly, the patterns of  
40 parental and household tobacco, nicotine and cannabis use and exposure will be  
41 mapped during pregnancy. Secondly, a range of biological samples will be collected  
42 to enable the first determination of Australian Indigenous people's nicotine and  
43 cannabis metabolism during pregnancy; this assessment will be informed by  
44 pharmacogenomic analysis. Thirdly, the pharmacokinetic and pharmacogenomic  
45 findings will be considered against maternal, placental, foetal and neonatal outcomes.

46 Lastly, an assessment of population health literacy and risk perception related to  
47 tobacco, nicotine and cannabis products peri-pregnancy will be undertaken.

48

49 **Methods:** This is a community-driven, co-designed, prospective, mixed-method  
50 observational study with regional Queensland parents expecting an Australian  
51 Indigenous baby and their close house-hold contacts during the peri-gestational  
52 period. The research utilises a multi-pronged and multi-disciplinary approach to  
53 explore interlinked objectives.

54

55 **Results:** A sample of 80 mothers expecting an Australian Indigenous baby will be  
56 recruited. This sample size will allow estimation of at least 90% sensitivity and  
57 specificity for the screening tool which maps the patterns of tobacco and nicotine use  
58 and exposure versus urinary cotinine with 95% CI within  $\pm 7\%$  of the point estimate.  
59 The sample size required for other aspects of the research is less (pharmacokinetic  
60 and genomic  $n=50$ , and the placental aspects  $n=40$ ), however from all 80 mothers, all  
61 samples will be collected.

62

63 **Conclusions:** Results will be reported using the STROBE guidelines for observational  
64 studies.

65

66 **Keywords:** Tobacco; nicotine; cannabis; exposure; pregnancy, pregnancy outcomes;  
67 Aboriginal and Torres Strait Islander; Australian Indigenous.

68

## 69 **Forward**

70 *We acknowledge the Traditional Custodians, the Butchulla people, of the lands and*  
71 *waters upon which this research is conducted. We acknowledge their continuing*  
72 *connections to country and pay our respects to Elders past, present and emerging.*

73

74 Notation: In this document, the terms Aboriginal and Torres Strait Islander and  
75 Indigenous are used interchangeably for Australia's First Nations People. No  
76 disrespect is intended, and we acknowledge the rich cultural diversity of the groups  
77 of peoples that are the Traditional Custodians of the land with which they identify  
78 and with whom they share a connection and ancestry.

## 79 **Introduction**

80

81 In 1957, Simpson [1] reported a dose-response association between maternal  
82 smoking and premature birth. This observation resulted in a world-wide research  
83 agenda focusing on the impact of maternal smoking in pregnancy, the findings of  
84 which indicate that maternal tobacco smoking, and exposure to the products of  
85 tobacco combustion (i.e., secondhand smoke exposure) are the leading modifiable  
86 risk behaviours associated with adverse maternal and neonatal outcomes. Maternal  
87 exposure increases the risk for miscarriage, ectopic pregnancy, antepartum bleeding,  
88 placental abruption, placenta previa, postpartum haemorrhage and alters maternal  
89 thyroid function [2, 3]. Counterintuitively, smoking in pregnancy is associated with  
90 decreased hypertensive disorders of pregnancy [4, 5]. For the foetus, maternal

91 exposure increases the risk of stillbirth, premature birth and lower birthweight [6] as  
92 well as increases the risk for a number of congenital abnormalities [7, 8]. Longer-  
93 term, offspring exposed in-utero to maternal smoking have decreased cognitive  
94 achievement [9] and an increased risk for the development of attention-  
95 deficit/hyperactivity disorder (ADHD) [10].

96

97 In Australia, these adverse pregnancy and foetal findings have ensured a prenatal  
98 focus on maternal smoking behaviour with the mother's cigarette smoking status  
99 obtained during antenatal assessment and recorded in the National Perinatal Data  
100 Collection [11] twice across the nine months of pregnancy (once < 20 weeks  
101 gestation, and once >20 weeks gestation). In that database, the 2021 rate of smoking  
102 by Australian non-Indigenous expectant mothers was reported as 11% compared  
103 with 42% by Australian Indigenous expectant mothers [12]. However, the maternal  
104 use of other tobacco and nicotine products including e-cigarettes, hookahs, chop-chop  
105 tobacco, nicotine tooth cleaning powder, chewing tobacco, and nicotine spray, mist,  
106 lozenges, gum and patches, and cannabis is not collected. In addition, this focus on  
107 maternal cigarette smoking fails to recognise second- and third-hand maternal  
108 nicotine vape and tobacco and cannabis smoke exposure, i.e., the impact from  
109 paternal and household tobacco, nicotine and cannabis exposure on maternal and  
110 foetal outcomes is overlooked.

111 This assessment gap results in maternal and foetal tobacco, nicotine and cannabis  
112 exposure misclassification and ramifications in the planning of care, and in the  
113 estimation of adverse maternal, placental, foetal and neonatal outcomes from

114 tobacco, nicotine and cannabis exposure. Nevertheless, the literature indicates that  
115 Indigenous babies exposed to maternal smoking have a higher rate of adverse  
116 outcomes compared to non-Indigenous babies exposed to maternal smoking, for  
117 example, after adjusting for maternal age and other factors, smoking in pregnancy is  
118 attributable to 22% of pre-term Indigenous births compared with 5% for non-  
119 Indigenous births [13]. Gestational age impacts birthweight, and for Indigenous  
120 mothers who smoked in the first 20 weeks of pregnancy, the risk of a lower  
121 birthweight baby was 1.8 (or about 80% higher risk) than among Indigenous mothers  
122 who did not smoke in the first 20 weeks. For non-Indigenous mothers who smoked  
123 in pregnancy, this risk was 1.3 (or 30% higher risk) [14].

124 The other significant foetal outcome attributable to maternal smoking is stillbirth. In  
125 Australia, stillbirth is defined as foetal death prior to birth of the baby at 20 weeks  
126 gestation or more, and/or weighing 400 grams or more [15]. In 2020, the overall  
127 Australian stillbirth rate was 7.7/1000 births, with the rate for Indigenous mothers  
128 being 11.9/1000 compared with 7.4/1000 for non-Indigenous mothers. Smoking in  
129 pregnancy is a risk factor for stillbirth; for women who smoked in pregnancy, the  
130 stillbirth rate was 12.8 stillbirths/1000 births compared to 6.9 stillbirths/1000 births  
131 for mothers who did not smoke [15]. Sub-category analysis of smoking and stillbirth  
132 for Indigenous mothers compared to non-Indigenous mothers is not published.

133

134 The reasons for the differences in pregnancy outcome between Indigenous and non-  
135 Indigenous pregnancies exposed to tobacco and nicotine are unknown but will be  
136 explored in this project through a number of activities.

## 137 **Background**

### 138 **Nicotine: pregnancy health and the developing human**

139

140 Currently, tobacco assessment in pregnancy is focused on ‘smoking’. This emphasis  
141 overlooks the absorption of the pharmacologically active, dose-dependent,  
142 potentially lethal component of tobacco-which is nicotine-from other sources [16].  
143 This study is premised on some of the actions of nicotine. In brief, nicotine binds with  
144 and activates nicotinic acetylcholine receptors (nAChR) in central and peripheral  
145 neuronal and non-neuronal tissue, at neuromuscular junctions, and in the adrenal  
146 medulla [17]. Receptor type and individual variability, including genetics and  
147 pregnancy, result in receptor up-regulation or desensitization [16, 18] and the release  
148 of neurotransmitters including acetylcholine, norepinephrine, dopamine, serotonin,  
149 vasopressin, beta-endorphin and adreno-corticotrophic-hormone, thus impacting the  
150 vasculature and producing vasoconstriction, increasing heart rate and blood pressure  
151 [19].

152

153 In pregnancy, nicotine acts both directly on nAChRs in the developing placenta,  
154 reducing the number of nAChR receptors [20], and alters placental morphology and  
155 vascularity [21]. Nicotine also readily crosses the placenta and stimulates nAChRs in  
156 the developing foetus impacting foetal systems, albeit in an immature physiology  
157 [22]. During early foetal development (4-6 weeks of gestation), nAChRs emerge and  
158 begin to form connections throughout the body including the brain [23], with

159 construction of axons and synaptic connections in the brain continuing after birth  
160 into childhood, adolescence and young adulthood [24]. In the foetal brain, nicotine  
161 exposure results in accelerated cell development relative to tissue and organ age, that  
162 is, there are fewer cells correctly developed for their stage and age [25]. Following  
163 nicotine exposure, changes in nAChRs and neural plasticity result in both a deficit in  
164 the number of neurons in the foetal brain and synaptic level damage to the  
165 respiratory center, with equivalent damage to the adrenal glands [26]. Foetal  
166 nicotine exposure ultimately results in a dampened response to hypoxic episodes  
167 [27]. These physiological changes are important in understanding links between  
168 maternal nicotine exposure and foetal outcomes, for example, stillbirth and Sudden  
169 Infant Death Syndrome (SIDS).

#### 170 **Nicotine metabolism and excretion**

171  
172 Nicotine has a half-life of about two hours and is metabolised via the CYP2A6 pathway  
173 primarily in the liver, with the brain, kidneys and lungs providing minor sites [28].  
174 This short half-life produces large nicotine serum plasma fluctuations and poses  
175 challenges for intra- and inter-person comparisons of exposure, consumption and  
176 effect. However, cotinine (the main tobacco and nicotine metabolite) has a half-life of  
177 approximately 17 hours and serum concentrations 10-fold higher than nicotine,  
178 providing a more stable biomarker of tobacco and nicotine exposure [29]. Cotinine  
179 begins to metabolise after approximately 16 hours into trans-3'-hydroxycotinine (3-  
180 OH-cotinine), nornicotine, nicotine glucuronide and nicotine-N-oxide [18]. A more



181 accurate assessment of tobacco and nicotine exposure is achieved by measuring  
182 serum tobacco and nicotine and metabolite concentrations (total nicotine equivalents  
183 – TNE), as opposed to measuring only nicotine concentration [30].

184

185 During pregnancy, nicotine metabolism is impacted both by individual variability  
186 [16] and the changes created by pregnancy. In the expectant mother, there is a  
187 significant induction of CYP2A6 activity which increases plasma clearances of  
188 nicotine by 60% and cotinine by 140%, in addition, there is an almost 50% reduction  
189 in cotinine half-life (down from 17 hours to 9 hours [31]). This is important in the  
190 consideration of tobacco and nicotine use in pregnancy as decreases in nicotine and  
191 cotinine measurements in late pregnancy compared with pre-pregnancy or early  
192 pregnancy may not necessarily indicate a decrease in tobacco and nicotine exposure,  
193 but rather the more rapid metabolism of nicotine [32]. In the foetus and neonate, the  
194 immature and undeveloped CYP2A6 pathway decreases their ability to metabolise  
195 nicotine and results in a much longer plasma nicotine half-life than adults (11.2 hours  
196 compared to 2 hours) whereas cotinine elimination is similar to that of adults (16.3  
197 hour half-life compared with 17 hours) [33].

198

199 CYP2A6, the major nicotine-oxidising enzyme, is measurable using the nicotine  
200 metabolite ratio (NMR; 3' hydroxycotinine:cotinine) and is a biomarker of nicotine  
201 clearance [16]. However, NMR is highly heritable (~80%) varying with ethnicity, in  
202 part due to CYP2A6 variants. Variation in CYP2A6 genes has not been characterised

203 in Australian Indigenous populations and may contribute to increased/decreased  
204 pregnancy risk from tobacco and nicotine exposure.

205

206 Tobacco, nicotine and the metabolites are rapidly excreted by the kidneys with the  
207 rate dependent upon urinary pH, where increased urine alkalinity decreases  
208 excretion [34]. Urinary excretion is further impacted in pregnancy due to elevated  
209 creatinine potentially leading to fluctuations in nicotine and its metabolites [35].  
210 Thus, serum provides a measure of exposure and the recency of that exposure, while  
211 urine analysis provides a measure of tobacco and nicotine metabolism and excretion.

## 212 **Materials and Methods**

### 213 **Aim and Objectives**

214

215 The aim of this study is to develop a foundation from which approaches to tobacco  
216 and nicotine assessment, health literacy, tobacco and nicotine cessation, and  
217 maternal and neonatal health care delivery for families expecting an Australian  
218 Indigenous baby is informed by contemporary evidence. Community input on the  
219 design suggested that cannabis use (with and without tobacco) is also prevalent and  
220 continues throughout pregnancy, thus cannabis use and exposure have been  
221 included.

222

223

224

225 The objectives are to:

- 226 1. Accurately describe parental and close household contact(s) peri-gestational  
227 patterns of use and exposure of tobacco, nicotine and cannabis products  
228 through the creation and use of a validated assessment tool.
- 229 2. Determine the pharmacokinetic and pharmacogenomic impacts and outcomes  
230 of tobacco, nicotine and cannabis exposure. This study will be the first to  
231 establish the metabolism of tobacco, nicotine and cannabis during pregnancy  
232 by using NMR as a biomarker of individual differences in nicotine and cannabis  
233 metabolism in a parental Australian Indigenous population.
- 234 3. Describe maternal, paternal, placental, foetal and neonatal outcomes  
235 according to the use and exposure to tobacco, nicotine and cannabis products  
236 and biochemical and genomic analysis.
- 237 4. Describe the influences and barriers to cessation for pregnant Australian  
238 Indigenous families or close household contacts to reduce or cease tobacco,  
239 nicotine and/or cannabis use in pregnancy.

240

#### 241 **Research Governance**

242 This project is centred around the local Australian Indigenous population in the  
243 Fraser Coast area (Queensland, Australia). The research will be conducted primarily  
244 from Galangoor Duwalami Primary Healthcare Service (the local Aboriginal and  
245 Torres Strait Islander Primary Health Service in Hervey Bay and Maryborough) and

246 at the Hervey Bay and Maryborough Hospitals within the Wide Bay Hospital and  
247 Health Service (WBHHS).

248

249 Galangoor Duwalami Primary Healthcare Service were consulted in regard to which  
250 Community members would best represent the Traditional Owners of the land where  
251 this research is to be conducted. A combined leadership group was formed which  
252 included the Butchulla Aboriginal Corporation and Butchulla Men's Business  
253 Association and this group advised, directed and oversaw the conversations around  
254 this research from its inception and arranged for discussions with the appropriate  
255 Community members. Under the Butchulla Aboriginal Corporation's Rule Book, the  
256 principal Objective of the corporation is to: 'Relieve poverty and disadvantage of the  
257 Butchulla People through the advancement of education, health, social or public  
258 welfare, and culture'. Accordingly, the Elders have approved this proposal and  
259 provided a Butchulla name for the project – *Ngabang* (mother), *Walbai* (baby), *Babun*  
260 (father). The project logo (Figure 1) reflects the aspirations of the Butchulla people  
261 for this project, which are to strive for a *healthy pregnancy*, which results in a *healthy*  
262 *family*, which maintains a *healthy culture*.

263

264

265 *Figure 1 Project logo*

266 The logo also recognises the governance of the project by the Butchulla people,

267 Galangoor Duwalami Primary Healthcare Service, the various Australian research

268 guidelines, and the collaborative nature of the project with other health providers  
269 and research-intensive organisations and academic partners. The project  
270 documentation, and staff and participant shirts and onesies carry this logo (Figure 2  
271 and 3)

272

273 *Figure 2 Participant shirt*

274 *Figure 3 Participant onesie*

## 275 **Research context**

276 Galangoor Duwalami Primary Healthcare Service generally maintain the sole care of  
277 the pregnant women until approximately 20 weeks gestation (unless they have a  
278 high-risk pregnancy). The mother then moves to a shared care model with the Hervey  
279 Bay and Maryborough Hospitals. In this project, data is collected across the entire  
280 pregnancy. The preferred site of data collection from Galangoor Duwalami Primary  
281 Healthcare Service patients will be at Galangoor Duwalami Primary Healthcare  
282 Service for as long as possible during the pregnancy, however some data collection  
283 will need to occur at antenatal visits at the Hervey Bay or Maryborough Hospitals. At  
284 birth (mostly likely at the Hervey Bay Hospital), biological samples will be collected,  
285 and birthing data will be collected on the participant's discharge from hospital.

## 286 **Inclusion and exclusion criteria and consent**

287 Potential participants who meet the following criteria will be invited to enrol in the  
288 study: pregnant mothers, aged 15 years or older at the time of enrollment, able to

289 understand English, able to provide informed consent, and who self-identify as being  
290 pregnant with an Australian Indigenous baby. In accordance with the value of Respect  
291 outlined in the National Statement of Ethical Conduct in Human Research [36], all  
292 potential maternal participants meeting the inclusion criteria will be carefully  
293 considered by the clinic midwife or healthcare medical officer to ensure the  
294 healthcare staff believe that potential enrolment is in the best interest of the  
295 participant at this point in their pregnancy. A list of suitable potential maternal  
296 participants will then be provided to the researchers; only those participants will be  
297 provided with research information.

298

299 The project will strive to enrol the family unit i.e., the mother, and the foetus, and the  
300 biological father, or non-biological parent partner (the parents), or one close  
301 household contact. For example, if an expectant mother lives with her sister or aunty  
302 or grandmother but there is no biological father in the family at that time, or there is  
303 a partner (of either gender) and that close family contact attends the antenatal visits  
304 with the maternal participant, that person will be invited to participate with the  
305 expectant mother. Family members do not have to participate; however, 'family' is  
306 central to Australian Indigenous people, and enrolling participants who constitute the  
307 cultural norm of family will be especially important in the translation of findings to  
308 the participant and the community.

309

310 Consent: Participants can choose to enrol in any or all aspects of the data and sample  
311 collection, and they can withdraw from any or all aspects of the research at any time.

312 The consent process enables participants to choose to have their individual results  
313 provided back to them at the completion of the project; for any or all samples to  
314 returned to the participant on completion of this project; or for the de-identified  
315 samples and de-identified data to be retained for ethically approved un-identified  
316 projects in the future. All enrolled participants will receive a participant shirt (Figure  
317 2), and liveborn newborns will receive a project onesie (Figure 3).

318

319 A subset of information-rich tobacco, nicotine and/or cannabis use/exposed  
320 participants will be enrolled into the separate male and female qualitative aspects of  
321 the study until saturation is reached (~30 participants). Data will be collected in  
322 response to a range of trigger questions and survey questions. Participants enrolled  
323 in the qualitative data collection will receive a \$50 grocery voucher in  
324 acknowledgement of their time to the project.

325

### 326 ***Tobacco, nicotine and cannabis use and exposure data and biological sample collection***

327 The quantitative data and sample collection for Objectives 1-3 is designed to  
328 measure maternal tobacco, nicotine and cannabis use, and maternal and foetal  
329 exposure, metabolism and excretion at varying times throughout the pregnancy and  
330 assess the findings against the maternal and foetal outcomes. At each antenatal  
331 appointment and at birth, tobacco, nicotine and cannabis use and exposure  
332 information will be collected on a *NicOTIne, tobacco, and Cannabis use and Exposure*  
333 *(NOTICE) Assessment Tool* (Figure 4 and see Box 1 NOTICE Notes).

334

335 *Figure 4 NOTICE: NicOTIne, tobacco, and Cannabis use and Exposure (NOTICE)*

336 Assessment Tool

337

338 **Box 1. NicOTIne tobacco, and Cannabis use and Exposure (NOTICE)**

339 **Assessment Tool – Notes.**

The NicOTIne tobacco, and Cannabis use and Exposure (NOTICE) assessment tool (Figure 4) has been developed by Angela Ratsch for this study to enable a comprehensive assessment of the use of smoked and smokeless tobacco and cannabis products as well as nicotine containing products. The tool also allows for the detailing of second-hand exposure, and is used in this protocol to inform the use and exposure of all products throughout the pregnancy. The recorded information facilitates a scoring method to determine the level of self-reported use and exposure to tobacco, nicotine and cannabis products (scored for the day of assessment, previous 24 hours, and the previous week).

A self-use weekly score will be calculated for each assessment completed. Scoring for self-use will be categorized for each product as: 0 - no use; 1 – low use (1 to 70 combusted or inhaled products); 2 – medium use (71-140 combusted or inhaled products); 3 – high use (141 + combusted or inhaled products). A self-use score will be calculated for each weekly product combusted or inhaled with the sum of these scores producing a total weekly self-use score with a range of 0-30. An exposure score will be calculated for each weekly product exposed to by multiplying the quantity exposed to score by the exposure. Exposure is categorized as 0 - no exposure; 1- some



limited exposure; 2 - moderate exposure or 3 - unrestricted exposure. A total weekly exposure score is then calculated by summing all the exposure scores with a range of 0-99 for each assessment completed.

The assessment takes about 3 minutes to complete and will be conducted at each antenatal visit and immediately prior to birth.

### **Exhaled breathe carbon monoxide (CO) assessment**

CO as a point of care (POC) assessment provides indicative information about combusted tobacco/cannabis use up to 24 hours previously. Exhaled CO monitors (Smokerlyser®) provide a CO ppm reading ranging between 0 and 30 and a percentage of oxygen replaced with CO on haemoglobin (%COHb) with higher readings indicating higher levels of combusted tobacco/cannabis use. The same device can measure foetal exposure as foetal carboxyhaemoglobin (%FCOHb). Readings for the level of CO ppm are categorized as:

- green—for no and general environmental combusted tobacco/cannabis exposure, indicated by CO <3 ppm for pregnant women, and CO <6 ppm for non-pregnant adults;
- orange—moderate combusted tobacco/cannabis exposure, indicated by CO 4-6 ppm for pregnant women, and CO 7-10 ppm in non-pregnant adults and;
- red—heavy combusted tobacco/cannabis exposure, indicated by CO >6 ppm for pregnant women, and CO >10 ppm in non-pregnant adults.

The assessment takes about 1 minute to complete and will be conducted at each antenatal visit and immediately prior to birth.

### **Saliva cotinine assessment**

The use of non-combusted tobacco products and nicotine substances, for example, chewed tobacco, e-cigarettes, nicotine patches and gum, does not create CO. Instead, cotinine saliva assessment (Oz Drug Tests®), as a POC measurement, can detect cotinine (the major metabolite of nicotine metabolism). The test has a cotinine cut-off value of 10 ng/mL and the expected window of detection for cotinine in saliva at 10 ng/mL is expected to be up to 2-3 days after the last nicotine use. The assessment takes about 3 minutes to complete and will be conducted at each antenatal visit and immediately prior to birth.

Procedure: The CO assessment will be conducted first, and if the CO level is within the yellow or red zone (high levels), a saliva test will not be conducted as these CO levels are indicative of combusted tobacco use and negates the requirement for saliva testing.

340

### 341 ***Sample collection process***

#### 342 *Mother*

343 At the first antenatal appointment, maternal urine, CO and saliva samples will be  
344 collected on a NOTICE Tool.

345 If the CO is within the orange or red zones, a cotinine saliva test will not be  
346 conducted. Also, during this first appointment, or when maternal bloods are being  
347 collected as part of standard care, maternal vein blood will be collected for this  
348 project.

- 349 • At each follow-up antenatal visit, maternal urine, CO and saliva (if indicated) will  
350 be collected and a NOTICE assessment completed.

351 *Biological father*

- 352 • At the first antenatal appointment, if the biological father is Indigenous, paternal  
353 vein blood, urine and semen will be collected and CO, saliva (if indicated), and a  
354 NOTICE assessment completed.

- 355 • At each follow-up visit, the biologically paternal CO and saliva (if indicated)  
356 samples will be measured and a NOTICE assessment completed.

357 *Non-biological parent, partner or close household member*

- 358 • At the first antenatal visit, the non-biological parent partner or close household  
359 contact will have a CO and saliva (if indicated) measured and a NOTICE  
360 assessment completed and these same tests will be conducted at each visit.

361 *Unaccompanied mother*

- 362 • If the biological father, partner or household member is not present, the expectant  
363 mother will report her exposure to the partner's and/or household member's  
364 combusted tobacco or heated nicotine (e-cigarette) as second-hand exposure on  
365 the NOTICE assessment tool.

366 *At birth*

- 367 • On presentation for birth, mothers will have a venous blood sample, urine, CO and  
368 saliva samples (if indicated) collected and a NOTICE assessment will be  
369 completed.
- 370 • At spontaneous or artificial rupture of membranes or caesarean birth, amniotic  
371 fluid will be collected.

- 372 • Following birth and the separation of the placenta from the mother and neonate,  
373 arterial and venous cord bloods will be collected from the placenta.
- 374 • The placenta will be weighed in grams, and measured in centimetres at two points,  
375 the widest and narrowest to estimate the area of the placenta. Placental  
376 photographs of the maternal and foetal side and the cord will be obtained.
- 377 • Placental samples for macro, micro-morphological and genomic examination will  
378 be obtained, rinsed in a solution of phosphate buffered saline and distilled water  
379 and then placed in a solution of RNA later. The placenta sent for standard  
380 histology.

381 *Postnatal*

- 382 • Following birth, neonates will have a Day 0-1 urine and meconium collected. If  
383 the neonate remains in hospital after Day 1, a further urine sample will be  
384 collected. The urine will be collected with the use of a standard adhesive urine  
385 collection device, and meconium will be collected from the nappy.
- 386 • Colostrum/breast milk will be collected when available. As active participants in  
387 the knowledge generation from this research, mothers will be encouraged to  
388 obtain their own colostrum/breast milk sample by hand/pump expression.

389 ***Clinical information***

390 Data contained in the Galangoor Duwalami Primary Healthcare Service and Hospital  
391 record including demographic, maternal, and neonatal data will be included in the  
392 research database. Pregnancy, labour and birthing information will be collected from  
393 the Queensland Health Perinatal Record following birth.

394 **Biological sample analysis.**

395 After labelling, participant samples will be stored in the appropriate solution and/or  
396 temperature control manner. Placental samples in RNA later will be transferred to  
397 the University of the Sunshine Coast for storage at -80°C. Other samples (excluding  
398 the whole placenta in formalin) will be transferred to the local Sullivan and Nicolaides  
399 Pathology at standard intervals. Sullivan and Nicolaides will then transfer directly to  
400 The University of Queensland for storage at -80°C. The placenta in formalin will be  
401 transferred to Queensland Pathology. The scientists undertaking the biological  
402 examinations and analysis will be blinded to the self-reported tobacco, nicotine and  
403 cannabis status of the participant.

404 Pregnancy elevates creatinine levels, potentially leading to fluctuations in the levels  
405 of nicotine and its metabolites and influencing cannabinoid levels [35]. To ensure the  
406 standardisation of these levels in urine samples during pregnancy, a creatinine  
407 analysis will be conducted. The biological samples will be initially analysed for  
408 tobacco, nicotine and their metabolites and cannabinoid concentration in ng/mg  
409 creatinine or nmol/mg creatinine for urine samples and ng/mL for other biological  
410 samples using standard procedures. Following this, the samples will undergo  
411 tobacco, nicotine and cannabinoid genomic assessment in relation to tobacco,  
412 nicotine and cannabis pharmacokinetics, and other examinations including thyroid  
413 antibodies, transthyretin and sENG levels and a genomic-wide analysis of tobacco  
414 nicotine and cannabis induced alterations will be conducted. In addition, the  
415 colostrum/breast milk microbiome will be considered for the impact of tobacco,  
416 nicotine and cannabis exposure.

417 **Qualitative data collection**

418 Information-rich participants will be invited to take part in a face-to-face interview  
419 and survey. The interview and survey will be in the form of a yarn [37-39] which will  
420 be conducted at a place of the participants choosing and audio recorded for review.  
421 Participants are welcome to have support people with them should they wish. Data  
422 will be responses to a range of trigger questions and survey questions to consider the  
423 barriers and influences to tobacco, nicotine and cannabis use and cessation, and to  
424 understand the population's health literacy and risk perception related to tobacco,  
425 nicotine and cannabis products peri-pregnancy. Participant's own language and slang  
426 will be used when possible. Data will be collected in a coded, but re-identifiable  
427 manner to enable researcher and participant follow-up. The code that will be used  
428 will be the same as for the participant's biological and clinical data collection. The  
429 codebook will be kept in a separate location to the recording. During the interviews,  
430 the participant will only be identified by the unique code.

431 **Outcome assessment**

432 Enrollment maternal blood and urine samples provide a baseline and are correlated  
433 to exhaled carbon monoxide (CO), cotinine saliva assessment, and the self-reported  
434 tobacco, nicotine and cannabis assessment tool (see Figure 4 and Notes: Table 1).  
435 At each antenatal visit, maternal urine is collected and correlated to the CO and saliva  
436 assessment and the self-reported tobacco, nicotine and cannabis assessment tool. At  
437 birth, a second maternal blood is taken to correlate to the excretion of nicotine and  
438 cannabis by the mother and neonate as measured in maternal and neonatal urine,

439 breast milk and meconium. The transfer of nicotine and cannabis to the fetus  
440 through the placenta and return to the mother is measured by amniotic fluid, arterial  
441 and venous cord blood, and placenta samples.

442

443 Outcomes include:

444 1. Parental and close household member's patterns of self-reported use and  
445 exposure to tobacco, nicotine and cannabis using the NOTICE Tool score. Total self-  
446 use and total exposure scores will be calculated by summing the total weekly quantity  
447 and exposure scores. Scores will then be categorised into clinically meaningful  
448 categories, with those reporting no exposure or use categorised as the reference  
449 group.

450 2. Tobacco, nicotine, cannabis and their metabolites concentration in ng/ml or  
451 nmol/ml. Concentrations of tobacco, nicotine, trans-3'-hydroxycotinine (3-OH-  
452 cotinine), nornicotine, nicotine glucuronide and nicotine N oxide, norcotinine, NNAL,  
453 nicotelline, anabasine and anatabine [40, 41] will be summed with the total  
454 concentration in each sample recorded as total nicotine equivalents (TNE) and the  
455 nicotine metabolite ratio (NMR: 3'-hydroxycotinine/cotinine) will be calculated [42].  
456 Similarly, delta-9-tetrahydrocannabinol-D3 (THC-D3) and delta-8 and/or delta-9  
457 carboxy tetrahydrocannabinol-D3 (THC-COOH-D3) will be measured and summed.

458 3. DNA methylation patterns influenced by tobacco, nicotine and cannabis use  
459 and exposure will be identified. Methylation levels will be assessed either by  
460 immunohistological analysis of methylation intermediates (5mC, 5-hmC) or  
461 calculated and expressed as  $\beta$  values ( $\beta$  = intensity of the methylated allele (M))/

462 (Intensity of the unmethylated allele (U) + intensity of the methylated allele (M) +  
463 100).

464 4. Specific tobacco, nicotine and cannabis induced genomic and DNA alterations  
465 related to the use and exposure tobacco, nicotine and cannabis products in the  
466 different participant groups (maternal, paternal, foetal placental and neonatal).  
467 Genotypes influenced by tobacco, nicotine and cannabis use and exposure will be  
468 identified. Genome-wide mRNA profiles will be sequenced and expressed as read  
469 counts per mRNA.

470 5. Identified genes and alternations (including gene expression) associated with  
471 tobacco, nicotine and cannabis metabolism and pregnancy clinical outcomes. Genes,  
472 including CYP2A6 and TCF7L2, with single nucleotide polymorphisms (SNPs) with  
473 minor allele frequency greater than 10% will be chosen for inclusion in analyses. PCR  
474 results will be reported as negative or positive.

475 6. Semen volume (mL) and quality including sperm concentrations (million per  
476 mL), count (million), progressive motility (%), vitality (%), morphology (%), pH (0-  
477 14), leucocyte counts (millions per mL).

478 7. CO readings will be used as continuous scores and also categorised as: 1)  
479 negligible combusted tobacco/cannabis exposure - indicated by <6 CO ppm for non-  
480 pregnant adults and <3 CO ppm for pregnant women; 2) light combusted  
481 tobacco/cannabis exposure - indicated by 7-10 CO ppm in non-pregnant adults and  
482 4-6 CO ppm for pregnant women; 3) heavy combusted tobacco/cannabis exposure -  
483 indicated by >10 CO ppm in non-pregnant adults and >6 CO ppm in pregnant women.



484 8. Saliva readings will be used as dichotomous scores, categorised as negative or  
485 positive

486 9. Maternal and neonatal outcomes including miscarriage, livebirth/stillbirth,  
487 gestational age (weeks), preterm birth (<37 weeks gestation), and birth weight  
488 (grams), pregnancy induced hypertension and pre-eclampsia, gestational diabetes,  
489 thyroid autoimmune disease, maternal anaemia and other factors of interest are  
490 listed in Supplementary Table 1.

491 ***Sample size***

492 Approximately 80 women expecting an Indigenous baby attend antenatal care at  
493 Galangoor Duwalami Primary Healthcare Service and the Hervey Bay and  
494 Maryborough Hospitals each year, and birth at the Hervey Bay Hospital.

495

496 Sample size to validate the NOTICE tool: To estimate the sensitivity and specificity of  
497 the NOTICE self-reported assessment tool for tobacco and nicotine use and exposure,  
498 assuming tobacco and nicotine exposure and use of 66% [43], a sample of 80 mothers  
499 with 5 or more assessments would allow estimation of at least 90% sensitivity and  
500 specificity for the screening tool for tobacco and nicotine use and exposure versus  
501 urinary cotinine with 95% CI within  $\pm 7\%$  of the point estimate [44]. The collection  
502 and validation of the additional tobacco and nicotine products increases both the  
503 sensitivity and specificity of the tool. Validation will be to POC CO, saliva cotinine, and  
504 blood and urine total nicotine equivalents [40, 41]. The collection of cannabis use and

505 exposure measured against urinary cannabinoid concentrations provides an  
506 assessment of the tool's broader utility in pregnancy.

507

508 Using multilevel linear regression modelling with urinary cotinine levels as an  
509 outcome and adjusted for tobacco and nicotine use and exposure, to estimate a  
510 statistically significant change in tobacco and nicotine metabolism during pregnancy  
511 in an Australian Aboriginal population, with a power of 80% and alpha level of 0.05,  
512 a total of 50 mothers would be required to have a minimum of five tobacco and  
513 nicotine urine measurements during pregnancy [45] assuming an intra-class  
514 correlation of 0.3 (or lower) between urinary cotinine levels for each mother during  
515 pregnancy. With a power of 80% and alpha level of 0.05, 34 placentas would be  
516 required to be examined to estimate a 50 cm<sup>2</sup> difference in area between high and  
517 low tobacco and nicotine use/exposure.

#### 518 ***Data analysis***

519 Following data cleaning, checking and validation, the participants' results from the  
520 NOTICE scores for tobacco, nicotine and cannabis use and exposure, the biochemical  
521 analysis from all biochemical samples, and the maternal and neonatal outcomes will  
522 be examined to address the research objectives as described in Table 1. All data  
523 analysis will be conducted using Stata 17 (Statacorp, Texas). Missing data and outliers  
524 will be examined and reported. Results will be reported with 95% confidence  
525 intervals (95% CI) and statistical significance at alpha 0.05.

526

**Table 1 Research outcomes and statistical analysis**

<p><b>Objective 1:</b> To accurately describe parental and close household contact(s) peri-gestational patterns of use and exposure to tobacco, nicotine and cannabis products through the creation and use of a validated assessment tool.</p>	
<p><b>Outcomes</b></p>	<p><b>Statistical analysis</b></p>
<p>a) Record parental and close house-hold member’s patterns of self-reported use and exposure to tobacco, nicotine and cannabis using the NOTICE tool.</p>	<p>a) Descriptive statistics of tobacco, nicotine and cannabis use and exposure self-reported assessment scores will be reported including frequency, means/medians and percentages. The score will be used as a continuous and/or ordinal categorical variable in analyses.</p>
<p>b) Conduct biochemical analysis of parental and neonatal samples for tobacco, nicotine and cannabis and metabolites.</p>	<p>b) Descriptive statistics of tobacco, nicotine and cannabis and metabolites levels from collected samples will be reported including frequency, means/medians and percentages. The levels will be used as a continuous and/or ordinal categorical variable in analyses. Participants will be categorised into faster or slower metabolism groups based on their plasma NMR, which is considered the most reliable measure [32, 46]. To ensure the normalization of distribution between the two groups, log-transformed NMR values will be used. In this study, log urine NMR will be utilized across three trimesters of pregnancy, serving as a non-invasive alternative to plasma NMR values. The association between plasma NMR and other NMR values obtained from other biological matrices will be investigated. Two groups (fast and slow metabolisers) will be compared based on their tobacco and nicotine use and exposure behaviours (e.g., cigarettes per day) and TNE levels from maternal urine samples. To assess nicotine exposure in newborn infants, TNE will be calculated for various biological samples including neonate urine, meconium, amniotic fluid, breast milk, and neonate blood samples. A Welch t-test analysis will be used to determine statistically significant differences between the two groups based on their NMR values. Additionally, a regression model will be utilized to present the association between NMR values using different biological matrices. The relationship between plasma NMR values, smoking behaviors, nicotine exposure on newborn babies, and TNE levels will be analysed using a regression model.</p>

<p>c) Compare maternal self-reported use and exposure with biochemical assessment of tobacco, nicotine and cannabis concentrations to establish the specificity, sensitivity and predictive validity of the NOTICE tool.</p>	<p>c) The sensitivity, specificity and predictive validity of the screening tool for tobacco, nicotine and cannabis use and exposure will be estimated by comparing self-reported scores with recorded cotinine saliva and CO levels at each antenatal visit.</p> <p>Reliability of the NOTICE tool will also be evaluated using linear regression with urinary nicotine, tobacco and metabolite levels as the outcome and the predictive value of the self-reported scores estimated.</p>
<p><b>Objective 2:</b> To determine the pharmacokinetic and pharmacogenomic impacts and outcomes of tobacco, nicotine and cannabis exposure.</p>	
<p><b>Outcomes</b></p>	<p><b>Data and Statistical analysis</b></p>
<p>a) Investigate specific tobacco, nicotine and cannabis-induced maternal, paternal, foetal, placental and neonatal genomic alternations related to the use and exposure to tobacco, nicotine and cannabis products.</p> <p>b) Determine tobacco, nicotine and cannabis metabolism by genotype (pharmacogenomics).</p> <p>c) Establish the pharmacokinetics of tobacco, nicotine and cannabis in this population.</p>	<p>a, b, c) Descriptive statistics will be used to report the frequency and proportion of participants with identified genetic factors related to the use of tobacco, nicotine and cannabis products. These factors will then be included in univariate and multivariate analyses as being present or absent to estimate their effect on clinical and biochemical outcomes.</p>
<p><b>Objective 3:</b> To describe maternal, paternal, placental, foetal and neonatal outcomes according to the use and exposure to tobacco, nicotine and cannabis products and biochemical and genomic analysis</p>	
<p><b>Outcomes</b></p>	<p><b>Data and Statistical analysis</b></p>
<p>a) Describe maternal, placental, foetal and neonatal outcomes</p>	<p>a) Descriptive statistics of maternal, placental, foetal and neonatal outcomes will be reported including frequency, means/medians and percentages.</p>
<p>b) Determine correlations maternal, paternal, placental and neonatal outcomes and parental and foetal</p>	<p>b) Using clinical knowledge and the literature, directed acyclic graphs (DAGs) will be constructed to aid identification of causal effects/associations between 1) clinical outcomes, 2) self-reported tobacco, nicotine and cannabis use, 3) tobacco,</p>

<p>tobacco, nicotine and cannabis biochemical concentrations/pharmacokinetics.</p>	<p>nicotine and cannabis metabolite concentrations, and 4) identified biomarkers, genetic/epigenomic/germline alterations, to determine which factors to include in statistical models.</p>
<p>c) Determine correlations between maternal, paternal, placental and neonatal outcomes and genomic factors.</p>	<p>c) Multilevel regression modelling will be used to account for the clustering effect (random effects) of each individual mother, to estimate adjusted odds ratios (logistic regression for dichotomous or categorial outcomes) or beta coefficients (linear regression for continuous data outcomes) and 95% CIs for associations. A range of adjustment factors will be considered as both fixed and random effects in the models including gestational age, infant sex, birth weight, preterm delivery, delivery method, post-partum haemorrhage, preeclampsia, maternal age, height, body mass index, parity, urinary tract infection, sexually transmitted infection, diabetes, hypertension, placental data.</p>
<p><b>Objective 4:</b> To describe the influences and barriers to cessation for pregnant Australian Indigenous women and their partners or close household contacts to reduce or cease tobacco and nicotine use in pregnancy</p>	
<p><b>Outcomes</b></p>	<p><b>Data and Statistical analysis</b></p>
<p>a) Qualitative exploration with information rich participants to understand the barriers and influences on tobacco, nicotine and cannabis cessation.</p> <p>b) Understand the population's health literacy and risk perception related to tobacco, nicotine and cannabis products peri-pregnancy.</p>	<p>a &amp; b) Data will be coded and analysis will follow established processes [47] with a preliminary thematic analysis assigning meaning to the data and generating categories and subcategories. The categories most often mentioned will be identified and similarities and dissimilarities detailed. The categories will then be further grouped, and themes and subthemes identified. These will be shared with the research team for review and modification as needed. The consensus themes will be organised for analysis using NVIVO 12.</p>

527 **Ethical approval**

528 This project has been approved by the Traditional Owners of the Fraser Coast area,  
529 the Butchulla people, in conjunction with Galangoor Duwalami Primary Healthcare  
530 Service. The project has the support of the Queensland Aboriginal and Torres Strait  
531 Islander Health Council (QAIHC) and has ethics approval from Qhealth  
532 (HREC/2021/QRBW/77758) and the University of Queensland (2021/HE002069).

533

534 **Discussion**

535 The overarching vision of this clinically derived, clinically driven, community based,  
536 mixed method project is to *Close the Gap* in Aboriginal and Torres Strait health  
537 outcomes. This project takes a life-course epidemiological approach to health  
538 outcomes, focusing on the start of life, that is, maternal and neonatal health to  
539 improve whole-of-life health outcomes.

540

541 Seventy years of evidence demonstrates that maternal tobacco smoking and exposure  
542 to combusted tobacco are the leading modifiable risk behaviours associated with  
543 adverse pregnancy outcomes [48]. Currently in Australia, the assessment for tobacco  
544 and nicotine exposure during pregnancy is focused on maternal cigarette use - no  
545 information on other forms of tobacco, nicotine or cannabis use and exposure is  
546 standardly collected or considered to inform clinical care. In addition, fathers or  
547 other household members are not asked about their tobacco, nicotine and cannabis

548 use. This limited (or absent) tobacco, nicotine and cannabis screening fails to address  
549 the broad range of contemporary products that are used in Australia and thus has  
550 ramifications for the mother, the father, the children, the clinician, Indigenous  
551 populations, and the broader profile of Australian health.

552

553 This project will be reported against the STOBE Guidelines and has purposeful and  
554 significant objectives. Firstly, the development of a validated tobacco and nicotine  
555 screening tool that can be translated to practice Australia-wide will enhance data  
556 reporting and the understanding of tobacco, nicotine and cannabis use and exposure  
557 to pregnancy outcomes. In addition, the use of a comprehensive and contemporary  
558 screening tool will provide an opportunity for women, families and health  
559 professionals to discuss tobacco, nicotine and cannabis use and reduction/cessation  
560 options.

561

562 Secondly, addressing the absence of literature related to the metabolism of nicotine  
563 and the influence of pharmacogenomic factors in Australian Indigenous populations  
564 will be transformative. As biotechnology has evolved, there has been an increasing  
565 recognition that genetics, epigenetics, and environmental interactions impact on  
566 health outcomes. The role of genomics in understanding population risks and  
567 targeting prevention or intervention programs to reduce risk or to provide treatment  
568 based on genomic knowledge (i.e., a precision medicine approach) is of enormous  
569 public health benefit. Genomic profiling allows for the understanding of different  
570 outcomes in different populations from the same exposure. Already research exists

571 that shows that nicotine is metabolised differently in genetically different populations  
572 [49-53] and particular risks are higher or lower in populations based on these genetic  
573 differences, however, this same level of understanding has not been established for  
574 Australian Indigenous parental populations. A genome-wide mapping of specific  
575 biological samples from the local Australian Indigenous parental population in  
576 relation to their potential risk from tobacco and nicotine use and exposure and  
577 establishing [the start of] a pharmacogenomic profile will structure a precision  
578 medicine approach to health care [54, 55] for this population.

579

580 Comprehension and appreciation of the barriers to tobacco, nicotine and cannabis  
581 cessation is an essential mechanism in supporting the decrease in tobacco, nicotine  
582 and cannabis use. Awareness these factors can lead to the construction of a range of  
583 education and support resources which can be selected by future pregnant women  
584 and the family to assist them to reduce or cease tobacco, nicotine and cannabis use in  
585 pregnancy.

586

587 Importantly, the findings from the tobacco, nicotine and cannabis assessment and  
588 analysis will be linked to maternal and neonatal outcomes. Using the screening tool  
589 as part of standard practice in the future will provide a predictive methodology,  
590 enabling expectant mothers, families and health services to better plan birthing and  
591 post-birthing needs in situations where tobacco, nicotine and cannabis exposure is an  
592 independent factor.

593



594 This research project is built on respect for the value of Indigenous perspectives and  
595 their contribution to the study. Indigenous knowledge systems are incorporated into  
596 the research methodology thereby mutually enriching the research. Translation to  
597 practice is an intended outcome of this project but will not be structured until findings  
598 are available. The intention is that translation will be informed by the Indigenous  
599 participants, the Aboriginal and Torres Strait Islander health service, the research-  
600 intensive organisations supporting this research and their researchers, and the chief  
601 researcher.

## 602 **Limitations**

603 The study consists of some strengths and limitations. One significant strength is the  
604 recording of tobacco, nicotine and cannabis use and exposure throughout early to late  
605 pregnancy and the collection of a range of biological samples that are used to  
606 measure:

- 607 • Recency of maternal tobacco and nicotine exposure (maternal CO, saliva, and  
608 maternal venous blood and urine),
- 609 • The transfer of nicotine to the foetus (venous cord blood, amniotic fluid and  
610 neonatal urine),
- 611 • The return of nicotine from the foetus (arterial cord blood)
- 612 • The longevity of exposure (placenta and meconium)

613

614 This approach minimises recall bias and provides a comprehensive and measurable  
615 assessment of tobacco and nicotine exposure over the duration of pregnancy.

616 However, the study will only recruit mothers expecting an Australian Indigenous  
617 baby in the Fraser Coast area which limits the generalizability of the findings.  
618 Additionally, being an observational study, the results will not provide the strongest  
619 evidence to establish a causal relationship between nicotine exposure or metabolism  
620 and pregnancy outcomes.

### 621 **Authors contributions**

622 AR: Conceptualization, design and methodology, establish collaborations and project  
623 administration, data collection, resources, writing original draft, review and editing.  
624 EAB: Data curation, formal analysis, investigation, methodology, software, validation,  
625 writing – review & editing. VB, JB, GM, MS: Conceptualization, supervision, writing –  
626 review & editing. GD, SO: Resources, supervision, writing – review & editing. AW:  
627 Conceptualization, methodology, resources, supervision, writing – review & editing.  
628 SB: Conceptualization, methodology, supervision, writing – review & editing. M-TW:  
629 Methodology, writing – review & editing. JM Methodology, supervision, validation,  
630 writing – review & editing. KJS: Methodology, resources, supervision, validation,  
631 writing – review & editing.

632

### 633 **Acknowledgements**

634 This project could not have developed without the overwhelming endorsement and  
635 governance of the Traditional Owners of the Fraser Coast area, the Butchulla people  
636 and the Butchulla Aboriginal Corporation and the Butchulla Men’s Business  
637 Association. Furthermore, this project cannot progress without the consistent and

638 positive leadership of GD, SO and SB at Galangoor Duwalami Primary Healthcare  
639 Service and the engaged involvement of the Galangoor Duwalami teams that wrap  
640 around and support the Indigenous expectant families of the Fraser Coast area.  
641 Moreover, the cooperation and involvement of maternal services and their support  
642 teams from Wide Bay Hospital and Health Services Fraser Coast is essential in  
643 ensuring this collaborative project can achieve its aim. Fraser Coast Sullivan and  
644 Nicolaides Pathology service are sentinel in the transport of biological samples to  
645 Brisbane and the University of Queensland and are providing this service pro bono.  
646 In terms of the design, AR conceived, designed the framework of the study, and will  
647 lead the data collection. AW, GM, VB, JB and MS guided the data collection design with  
648 Indigenous mothers and families and consulted with their respective Indigenous  
649 organisations and community members to ensure cultural and community safety and  
650 expectations were established. LB designed the statistical analysis and will undertake  
651 the data analysis. M-TW will undertake the biochemical analysis as a PhD Scholar at  
652 the University of Queensland under the supervision of JM and KS. AR is partially  
653 funded under a QHealth Advancing Clinical Research Fellowship.

654

#### 655 **Conflicts of Interest**

656 None declared.

#### 657 **Abbreviations**

658 ADHD – attention-deficit/hyperactivity disorder

659 CO - carbon monoxide

660 DAGs - directed acyclic graphs

661 mRNA - messenger ribonucleic acid

662 nAChR - nicotinic acetylcholine receptors

663 NMR - nicotine metabolite ratio

664 NRT - nicotine replacement therapy

665 POC - point of care

666 QAIHC - Queensland Aboriginal and Torres Strait Islander Health Council

667 NOTICE - Ratsch Assessment of Tobacco and Nicotine

668 SIDS - sudden infant death syndrome

669 SNPs - single nucleotide polymorphisms

670 TNE - total nicotine equivalents

671

672

673 **Supporting Information.** Supplementary Table 1: Variables of interest for analysis

674 extracted from standard National Perinatal Data Collection report, together with

675 variables of interest for this project (i.e., tobacco, nicotine and cannabis use and

676 exposure)

677

## 678 **References**

679


- 680 1. Simpson WJ. A preliminary report on cigarette smoking and the incidence of  
681 prematurity. *Am J Obstet Gynecol.* 1957;73(4):807-15.
- 682 2. Avsar TS, McLeod H, Jackson L. Health outcomes of smoking during  
683 pregnancy and the postpartum period: an umbrella review. *BMC Pregnancy*  
684 *Childbirth.* 2021;21(1):254.
- 685 3. Naeye RL. Abruptio placentae and placenta previa: frequency, perinatal  
686 mortality, and cigarette smoking. *Obstet Gynecol.* 1980;55(6):701-4.
- 687 4. Marcoux S, Brisson J, Fabia J. The effect of cigarette smoking on the risk of  
688 preeclampsia and gestational hypertension. *Am J Epidemiol.* 1989;130(5):950-7.
- 689 5. England LJ, Levine RJ, Qian C, Morris CD, Sibai BM, Catalano PM, et al.  
690 Smoking before pregnancy and risk of gestational hypertension and preeclampsia.  
691 *Am J Obstet Gynecol.* 2002;186(5):1035-40.
- 692 6. Gould GS, Havard A, Lim LL, The Psanz Smoking In Pregnancy Expert G,  
693 Kumar R. Exposure to Tobacco, Environmental Tobacco Smoke and Nicotine in  
694 Pregnancy: A Pragmatic Overview of Reviews of Maternal and Child Outcomes,  
695 Effectiveness of Interventions and Barriers and Facilitators to Quitting. *Int J Environ*  
696 *Res Public Health.* 2020;17(6).
- 697 7. Hackshaw A, Rodeck C, Boniface S. Maternal smoking in pregnancy and birth  
698 defects: a systematic review based on 173 687 malformed cases and 11.7 million  
699 controls. *Hum Reprod Update.* 2011;17(5):589-604.
- 700 8. Yang L, Wang H, Yang L, Zhao M, Guo Y, Bovet P, et al. Maternal cigarette  
701 smoking before or during pregnancy increases the risk of birth congenital  
702 anomalies: a population-based retrospective cohort study of 12 million mother-  
703 infant pairs. *BMC Med.* 2022;20(1):4.
- 704 9. Clifford A, Lang L, Chen R. Effects of maternal cigarette smoking during  
705 pregnancy on cognitive parameters of children and young adults: a literature  
706 review. *Neurotoxicol Teratol.* 2012;34(6):560-70.
- 707 10. Sourander A, Sucksdorff M, Chudal R, Surcel HM, Hinkka-Yli-Salomaki S,  
708 Gyllenberg D, et al. Prenatal Cotinine Levels and ADHD Among Offspring. *Pediatrics.*  
709 2019;143(3).
- 710 11. Australian Institute of Health and Welfare. [Internet]. Canberra: National  
711 Perinatal Data Collection (NPDC): Australian Government; 2020 [cited 2024 3  
712 January]. Available from: [https://www.aihw.gov.au/about-our-data/our-data-](https://www.aihw.gov.au/about-our-data/our-data-collections/national-perinatal-data-collection)  
713 [collections/national-perinatal-data-collection](https://www.aihw.gov.au/about-our-data/our-data-collections/national-perinatal-data-collection).
- 714 12. Australian Institute of Health and Welfare. [Internet]. Australia's mothers  
715 and babies; 2023 [cited 2024 3 January]. Available from:  
716 [https://www.aihw.gov.au/reports/mothers-babies/australias-mothers-](https://www.aihw.gov.au/reports/mothers-babies/australias-mothers-babies/contents/about)  
717 [babies/contents/about](https://www.aihw.gov.au/reports/mothers-babies/australias-mothers-babies/contents/about).
- 718 13. Australian Institute of Health and Welfare, National Indigenous Australian  
719 Agency. [Internet]. Canberra: Tier 2 Determinants of health 2.21 Health behaviours  
720 during pregnancy: Australian Government; 2022 [cited 2024 5 January]. Available  
721 from: [https://www.indigenoushpf.gov.au/measures/2-21-health-behaviours-](https://www.indigenoushpf.gov.au/measures/2-21-health-behaviours-during-pregnancy)  
722 [during-pregnancy](https://www.indigenoushpf.gov.au/measures/2-21-health-behaviours-during-pregnancy).

- 723 14. Australian Institute of Health and Welfare. [Internet]. Canberra: Pregnancy  
724 and birth outcomes for Aboriginal and Torres Strait Islander women 2016–2018.  
725 Cat. no. IHW 234: AIHW; 2021 [cited 2023 14 October]. Available from:  
726 [https://www.aihw.gov.au/reports/indigenous-australians/pregnancy-birth-](https://www.aihw.gov.au/reports/indigenous-australians/pregnancy-birth-outcomes-indigenous-women-2016-18/contents/summary)  
727 [outcomes-indigenous-women-2016-18/contents/summary](https://www.aihw.gov.au/reports/indigenous-australians/pregnancy-birth-outcomes-indigenous-women-2016-18/contents/summary).  
728 15. Australian Institute of Health and Welfare. [Internet]. Canberra: Stillbirths  
729 and neonatal deaths in Australia 2017 and 2018: AIHW; 2021 [cited 2024 24  
730 January]. Available from: [https://www.aihw.gov.au/getmedia/4b6ff4e5-f549-42c7-](https://www.aihw.gov.au/getmedia/4b6ff4e5-f549-42c7-96ac-e6cc221d79b8/aihw-per-115.pdf.aspx)  
731 [96ac-e6cc221d79b8/aihw-per-115.pdf.aspx](https://www.aihw.gov.au/getmedia/4b6ff4e5-f549-42c7-96ac-e6cc221d79b8/aihw-per-115.pdf.aspx).  
732 16. Benowitz NL, Hukkanen J, Jacob P, III. Nicotine Chemistry, Metabolism,  
733 Kinetics and Biomarkers. In: Henningfield JE, London ED, Pogun S, editors. Nicotine  
734 Psychopharmacology. Handbook of Experimental Pharmacology. 192: Springer  
735 Berlin Heidelberg; 2009. p. 29-60.  
736 17. McGrath-Morrow SA, Gorzkowski J, Groner JA, Rule AM, Wilson K, Tanski SE,  
737 et al. The Effects of Nicotine on Development. *Pediatrics*. 2020;145(3).  
738 18. Hukkanen J, Jacob P, 3rd, Benowitz NL. Metabolism and disposition kinetics  
739 of nicotine. *Pharmacol Rev*. 2005;57(1):79-115.  
740 19. Tizabi Y, Getachew B, Copeland RL, Aschner M. Nicotine and the nicotinic  
741 cholinergic system in COVID-19. *FEBS J*. 2020;287(17):3656-63.  
742 20. Banerjee S, Deacon A, Suter MA, Aagaard KM. Understanding the Placental  
743 Biology of Tobacco Smoke, Nicotine, and Marijuana (THC) Exposures During  
744 Pregnancy. *Clin Obstet Gynecol*. 2022;65(2):347-59.  
745 21. Pintican D, Poienar AA, Strilciuc S, Miha D. Effects of maternal smoking on  
746 human placental vascularization: A systematic review. *Taiwan J Obstet Gynecol*.  
747 2019;58(4):454-9.  
748 22. Beltrán-Castillo S, Bravo K, Eugén J. Impact of Prenatal Nicotine Exposure  
749 on Placental Function and Respiratory Neural Network Development. In: Gonzalez-  
750 Ortiz M, editor. *Advances in Maternal-Fetal Biomedicine: Cellular and Molecular*  
751 *Mechanisms of Pregnancy Pathologies*. Cham: Springer International Publishing;  
752 2023. p. 233-44.  
753 23. Alzu'bi A, Middleham W, Shoaib M, Clowry GJ. Selective Expression of  
754 Nicotinic Receptor Sub-unit mRNA in Early Human Fetal Forebrain. *Front Mol*  
755 *Neurosci*. 2020;13:72.  
756 24. National Research Council (US) and Institute of Medicine (US) Committee on  
757 Integrating the Science of Early Childhood Development. [Internet]. Washington  
758 (DC): From Neurons to Neighborhoods: The Science of Early Childhood  
759 Development. *The Developing Brain: National Academies Press* 2000 [cited 2024 29  
760 January]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK225562/>.  
761 25. Slotkin TA. If nicotine is a developmental neurotoxicant in animal studies,  
762 dare we recommend nicotine replacement therapy in pregnant women and  
763 adolescents? *Neurotoxicol Teratol*. 2008;30(1):1-19.  
764 26. Buck JM, O'Neill HC, Stitzel JA. Developmental nicotine exposure elicits  
765 multigenerational disequilibria in proBDNF proteolysis and glucocorticoid signaling  
766 in the frontal cortices, striata, and hippocampi of adolescent mice. *Biochem*  
767 *Pharmacol*. 2019;168:438-51.

- 768 27. Bednarczuk N, Milner A, Greenough A. The Role of Maternal Smoking in  
769 Sudden Fetal and Infant Death Pathogenesis. *Front Neurol.* 2020;11:586068.
- 770 28. Benowitz NL. Clinical pharmacology of nicotine. *Annu Rev Med.* 1986;37:21-  
771 32.
- 772 29. Benowitz NL, Kuyt F, Jacob P, 3rd, Jones RT, Osman AL. Cotinine disposition  
773 and effects. *Clin Pharmacol Ther.* 1983;34(5):604-11.
- 774 30. Benowitz NL, Dains KM, Dempsey D, Yu L, Jacob P, 3rd. Estimation of nicotine  
775 dose after low-level exposure using plasma and urine nicotine metabolites. *Cancer*  
776 *Epidemiol Biomarkers Prev.* 2010;19(5):1160-6.
- 777 31. Dempsey D, Jacob P, 3rd, Benowitz NL. Accelerated metabolism of nicotine  
778 and cotinine in pregnant smokers. *J Pharmacol Exp Ther.* 2002;301(2):594-8.
- 779 32. Arger CA, Taghavi T, Heil SH, Skelly J, Tyndale RF, Higgins ST. Pregnancy-  
780 Induced Increases in the Nicotine Metabolite Ratio: Examining Changes During  
781 Antepartum and Postpartum. *Nicotine Tob Res.* 2019;21(12):1706-10.
- 782 33. Dempsey D, Jacob P, 3rd, Benowitz NL. Nicotine metabolism and elimination  
783 kinetics in newborns. *Clin Pharmacol Ther.* 2000;67(5):458-65.
- 784 34. Feyerabend C, Russell MAH. Effect of urinary pH and nicotine excretion rate  
785 on plasma nicotine during cigarette smoking and chewing nicotine gum. *Br J Clin*  
786 *Pharmacol.* 1978;5(4):293-7.
- 787 35. Taghavi T, Arger CA, Heil SH, Higgins ST, Tyndale RF. Longitudinal Influence  
788 of Pregnancy on Nicotine Metabolic Pathways. *Journal of Pharmacology and*  
789 *Experimental Therapeutics.* 2018;364(2):238-45.
- 790 36. The National Health and Medical Research Council, the Australian Research  
791 Council, and Universities Australia. National Statement on Ethical Conduct in Human  
792 Research 2007 (Updated 2018). Canberra: Commonwealth of Australia; 2018.
- 793 37. Geia LK, Hayes B, Usher K. Yarning/Aboriginal storytelling: towards an  
794 understanding of an Indigenous perspective and its implications for research  
795 practice. *Contemp Nurse.* 2013;46(1):13-7.
- 796 38. Bessarab D, Ng'andu B. Yarning About Yarning as a Legitimate Method in  
797 Indigenous Research. *International Journal of Critical Indigenous Studies.*  
798 2010;3(1):37-50.
- 799 39. Walker M, Fredericks B, Mills K, Anderson D. "Yarning" as a method for  
800 community-based health research with Indigenous women: the Indigenous  
801 Women's Wellness Research Program. *Health Care Women Int.* 2014;35(10):1216-  
802 26.
- 803 40. Benowitz NL, Bernert JT, Foulds J, Hecht SS, Jacob P, Jarvis MJ, et al.  
804 Biochemical Verification of Tobacco Use and Abstinence: 2019 Update. *Nicotine Tob*  
805 *Res.* 2020;22(7):1086-97.
- 806 41. Benowitz NL, St Helen G, Nardone N, Cox LS, Jacob P. Urine Metabolites for  
807 Estimating Daily Intake of Nicotine From Cigarette Smoking. *Nicotine Tob Res.*  
808 2020;22(2):288-92.
- 809 42. Benowitz NL, Pomerleau OF, Pomerleau CS, Jacob P, III. Nicotine metabolite  
810 ratio as a predictor of cigarette consumption. *Nicotine Tobacco Res.* 2003;5(5):621-  
811 4.

- 812 43. Gilligan C, Sanson-Fisher R, Eades S, Wenitong M, Panaretto K, D'Este C.  
813 Assessing the accuracy of self-reported smoking status and impact of passive smoke  
814 exposure among pregnant Aboriginal and Torres Strait Islander women using  
815 cotinine biochemical validation. *Drug Alcohol Rev.* 2010;29(1):35-40.
- 816 44. Malhotra RK, Indrayan A. A simple nomogram for sample size for estimating  
817 sensitivity and specificity of medical tests. *Indian J Ophthalmol.* 2010;58(6):519-22.
- 818 45. McNeish DM. Modeling sparsely clustered data: design-based, model-based,  
819 and single-level methods. *Psychol Methods.* 2014;19(4):552-63.
- 820 46. Vaz LR, Coleman T, Cooper S, Aveyard P, Leonardi-Bee J, team St. The  
821 Nicotine Metabolite Ratio in Pregnancy Measured by trans-3'-Hydroxycotinine to  
822 Cotinine Ratio: Characteristics and Relationship With Smoking Cessation. *Nicotine  
823 Tob Res.* 2015;17(11):1318-23.
- 824 47. Braun V, Clarke V. Using thematic analysis in psychology. *Qualitative  
825 Research in Psychology.* 2006;3(2):77-101.
- 826 48. National Center for Chronic Disease Prevention and Health Promotion (US)  
827 Office on Smoking and Health. Reproductive Outcomes. *The Health Consequences of  
828 Smoking—50 Years of Progress: A Report of the Surgeon General.* Atlanta (GA):  
829 Centers for Disease Control and Prevention (US); 2014. p. 461-521.
- 830 49. Benowitz NL, Perez-Stable EJ, Herrera B, Jacob P, 3rd. Slower metabolism and  
831 reduced intake of nicotine from cigarette smoking in Chinese-Americans. *J Natl  
832 Cancer Inst.* 2002;94(2):108-15.
- 833 50. Cecil CA, Walton E, Smith RG, Viding E, McCrory EJ, Relton CL, et al. DNA  
834 methylation and substance-use risk: a prospective, genome-wide study spanning  
835 gestation to adolescence. *Transl Psychiatry.* 2016;6(12):e976.
- 836 51. Chen X, Woodcroft KJ. Polymorphisms in metabolic genes CYP1A1 and  
837 GSTM1 and changes in maternal smoking during pregnancy. *Nicotine Tob Res.*  
838 2009;11(3):225-33.
- 839 52. Keskitalo K, Broms U, Heliovaara M, Ripatti S, Surakka I, Perola M, et al.  
840 Association of serum cotinine level with a cluster of three nicotinic acetylcholine  
841 receptor genes (CHRNA3/CHRNA5/CHRNA4) on chromosome 15. *Hum Mol Genet.*  
842 2009;18(20):4007-12.
- 843 53. Marceau K, Palmer RH, Neiderhiser JM, Smith TF, McGuey JE, Knopik VS.  
844 Passive rGE or developmental gene-environment cascade? An investigation of the  
845 role of xenobiotic metabolism genes in the association between smoke exposure  
846 during pregnancy and child birth weight. *Behav Genet.* 2016;46(3):365-77.
- 847 54. Allenby CE, Boylan KA, Lerman C, Falcone M. Precision Medicine for Tobacco  
848 Dependence: Development and Validation of the Nicotine Metabolite Ratio. *J  
849 Neuroimmune Pharmacol.* 2016;11(3):471-83.
- 850 55. Cheng YY, Nunn J, Skinner J, Rambaldini B, Boughtwood T, Calma T, et al. A  
851 Pathway to Precision Medicine for Aboriginal Australians: A Study Protocol.  
852 *Methods Protoc.* 2021;4(2):42.  
853





Project logo



Participant polo



Participant Onesie

## NicOTIne, tobacco and Cannabis use and Exposure (NOTICE) assessment tool

To calculate self-use (SU) score:

Self-Use score calculated for each **weekly** product.

Quantity reported	Use	Score
0	None	0
1 - 70	Low	1
71 - 140	Medium	2
141 +	High	3

Total self-use score = sum of all weekly self-use scores.

To calculate total exposure (E) score:

Exposure score calculated for each **weekly** product exposed to.

Quantity	Exposure	Quantity Score
0	None	0
1 - 70	Low	1
71 - 140	Medium	2
141 +	High	3

Exposure	Exposure
0	No known exposure
1	Some limited exposure, e.g. outdoor
2	Moderate exposure, e.g. indoor but restricted to certain areas
3	No restriction, e.g. full exposure in the house, in bedroom or car.

Exposure score = weekly quantity score x weekly exposure score (range 0 – 9)

Total exposure score = sum of all exposure scores.